Company NewsNews HighlightRAG-17 Ractigen Therapeutics Receives IND Approval from China’s NMPA to Initiate Phase 1 Clinical Trials for RAG-17 in SOD1-ALS Patients JIANGSU, CHINA (May 15, 2024) – Ractigen Therapeutics, a clinical-stage pharmaceutical company committed to developing…ractigenMay 15, 2024
Company NewsHomepage NewsNews HighlightRAG-01 Ractigen Therapeutics Announces FDA Approval for RAG-01, a First-in-Class saRNA Therapy for BCG-Unresponsive NMIBC JIANGSU, China, April 26, 2024 — Ractigen Therapeutics, a leader in the development of small…ractigenApril 26, 2024
Company NewsRAG-01 Ractigen Announces First Patient Dosed in the Phase I Clinical Trial of RAG-01 for NMIBC JIANGSU, China, April 3, 2024 – Ractigen Therapeutics, a pioneer in small activating RNA (saRNA) therapeutics,…ractigenApril 3, 2024
Company News Ractigen Therapeutics Enters Strategic Partnership with University Medical Center Utrecht to Drive saRNA Innovation in Neurodevelopmental Disorders Suzhou, China – January 29, 2024 – Ractigen Therapeutics, a clinical-stage pharmaceutical company leading the…ractigenJanuary 29, 2024
Company NewsHomepage NewsRAG-01 Ractigen Therapeutics Advances into Clinical Stage with Groundbreaking saRNA Drug, RAG-01 JIANGSU, China, Dec. 06, 2023 — Ractigen Therapeutics, a leader in the field of small…ractigenDecember 6, 2023
Company News Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting Findings support saRNA as a therapeutic strategy to compensate dystrophin’s function by upregulating UTRN expression…EnvisionNovember 2, 2023
Company NewsRAG-17 Ractigen Therapeutics Announces Dosing of First Patient in First in Human Trial of RAG-17 for the Treatment of SOD1-ALS Study aims to evaluate the safety and feasibility of RAG-17 in human patients and clinically validate Ractigen’s…EnvisionJune 10, 2023
Company News Ractigen Therapeutics Announces Dosing of First Patient in First in Human Trial of RAG-17 for the Treatment of SOD1-ALS Study aims to evaluate the safety and feasibility of RAG-17 in human patients and clinically…ractigenJune 10, 2023
Company NewsRAG-17 Ractigen Therapeutics Receives FDA Orphan Drug Designation for the novel oligonucleotide conjugate RAG-17 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) Jiangsu, China — Ractigen Therapeutics announced today that the U.S. Food and Drug Administration (FDA)…EnvisionMarch 3, 2023
Company NewsHomepage News Ractigen Therapeutics closes an additional $30 million in Series A+ funding to push development of its RNAa platform Ractigen Therapeutics today announced the closing of a Series A+ financing round totaling $30 million…EnvisionJanuary 27, 2022